ImmuCell Corporation reported preliminary, unaudited sales results for the fourth quarter and full year of 2025. Total sales for the three months ended December 31, 2025, were $7.6 million, representing a 1.6% decline compared to the same period in 2024. For the full year, domestic sales reached $24.4 million, a 6.5% increase from 2024, while international sales were $3.3 million, a 9.6% decrease compared to the previous year. The Tri-Shield® product line generated $19.9 million in sales in 2025, a 26.5% increase year-over-year. In contrast, sales of Dual-Force® and other products totaled $7.7 million, marking a 28.2% decline from 2024. The company also announced a strategic focus on expanding its First Defense® product line after receiving a United States Food and Drug Administration (FDA) Incomplete Letter for its Re-Tain® product due to unresolved inspectional deficiencies by its contract manufacturer. ImmuCell plans to record an approximately $2.9 million non-cash impairment write-down of property, plant, and equipment related to Re-Tain® in the fourth quarter of 2025. The company intends to repurpose the majority of the Re-Tain® assets to support First Defense® production. Manufacturing improvements in 2025 increased lyophilization process output by over 15% year-over-year, and similar improvements are planned for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622573) on January 08, 2026, and is solely responsible for the information contained therein.